Medtronic has presented new data from the randomized, double-blind Adaptive CRT study evaluating the clinical benefit of synchronized left ventricular pacing provided by the company’s exclusive AdaptivCRT algorithm.


According to Medtronic, the new data showed a 61% lower risk of atrial fibrillation-related problems in patients who received a cardiac resynchronization therapy-defibrillator (CRT-D) with the AdaptivCRT algorithm compared to conventional biventricular pacing therapy.

The data also showed a 55% relative reduction in healthcare utilizations when patients have devices with AdaptivCRT.

The new study supplements earlier data showing reduction in hospital readmissions for heart failure patients with AdaptivCRT technology.

Earlier data from the Adaptive CRT trial showed patients with heart failure who received the AdaptivCRT technology were at a 46% lower risk of spending 48 consecutive hours or more in atrial fibrillation compared to conventional CRT patients.

Medtronic plans to conduct a global study of 3,000 patients to assess the superiority of CRT with AdaptivCRT therapy in reducing heart failure events and mortality, compared to conventional bi-ventricular pacing.

Medtronic Viva CRT-D and Viva CRT-P devices has the AdaptivCRT feature that works by preserving normal heart rhythms and automatically adjusting to the patient’s needs every minute, creating a customized therapy for each patient.

The multicenter Adaptive CRT study enrolled 522 patients who received a CRT device and were randomized to either receive the AdaptivCRT algorithm (treatment arm) or conventional CRT with echocardiographic optimization of the pacing parameters (control arm)in a 2:1 ratio.

All patients in the study were followed at six and 12 months and subsequently every six months until study closure. Overall, the Adaptive CRT trial showed non-inferiority of the AdaptivCRT algorithm to echocardiographically optimized CRT.

Image: Medtronic’s VivaXT CRT-D device. Photo: Courtesy of Medtronic, Inc.